Taxol, Camptothecin and Beyond for Cancer Therapy

Advances in Botanical Research

Volumn 62, Issue , 2012, Pages 133-178

  Lee, Wai Leng ^a   Shiau, Jeng Yuan ^a   Shyur, Lie Fen ^a  

^a AGRICULTURAL BIOTECHNOLOGY RESEARCH CENTER   (Taiwan)

Author keywords

Anti cancer drugs; Camptothecin; Docetaxel; Paclitaxel; Taxol

Indexed keywords

EID: 84862677508     PISSN: 00652296     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-394591-4.00008-8     Document Type: Chapter

References (244)

1. Adams J.M., Cory S. The Bcl-2 protein family: Arbiters of cell survival. Science 1998, 281:1322-1326.
2. Adams D.J., Dewhirst M.W., Flowers J.L., Gamcsik M.P., Colvin O.M., Manikumar G., Wani M.C., Wall M.E. Camptothecin analogues with enhanced antitumor activity at acidic pH. Cancer Chemotherapy and Pharmacology 2000, 46:263-271.
3. Aggarwal B.B., Shishodia S., Takada Y., Banerjee S., Newman R.A., Bueso-Ramos C.E., Price J.E. Curcumin suppresses the paclitaxel-induced nuclear factor-kappa B pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clinical Cancer Research 2005, 11:7490-7498.
4. Andrade-Cetto A., Heinrich M. From the field into the lab: Useful approaches to selecting species based on local knowledge. Frontiers in Pharmacology 2011, 2:1-5.
5. Baldwin A.S. Control of oncogenesis and cancer therapy resistance by the transcriptional factor nuclear factor-kappa B. Journal of Clinical Investigation 2001, 107:241-246.
6. Balunas M.J., Kinghorn A.D. Drug discovery from medicinal plants. Life Sciences 2005, 78:431-441.
7. Basili S., Moro S. Novel camptothecin derivatives as topoisomerase I inhibitors. Expert Opinion on Therapeutic Patents 2009, 19:555-574.
8. Basu A., Dubois G., Haldar S. Posttranslational modifications of Bcl-2 family members-A potential therapeutic target for human malignancy. Frontiers in Bioscience 2006, 11:1508-1521.
9. Bayet-Robert M., Kwiatowski F., Leheurteur M., Gachon F., Planchat E., Abrial C., Mouret-Reynier M.A., Durando X., Barthomeuf C., Chollet P. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biology & Therapy 2010, 9:8-14.
10. Bennasar M.L., Zulaica E., Juan C., Alonso Y., Bosch J. Addition of ester enolates to N-alkyl-2-fluoropyridinium salts: Total synthesis of (+/-)-20-deoxycamptothecin and (+)-camptothecin. Journal of Organic Chemistry 2002, 67:7465-7474.
11. Bernhoft A. Bioactive Compounds in Plants-Benefits and Risks for Man and Animals 2010, The Norwegian Academy of Science and Letters, AIT Otta AS, Oslo, Norway.
12. Bhalla K.N. Microtubule-targeted anticancer agents and apoptosis. Oncogene 2003, 22:9075-9086.
13. Bhalla K., Ibrado A., Tourkina E., Tang C., Mahoney M., Huang Y. Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia 1993, 7:563-568.
14. Blagg B.S.J., Boger D.L. Total synthesis of (+)-camptothecin. Tetrahedron 2002, 58:6343-6349.
15. Blagosklonny M.V. Mitotic arrest and cell fate: Why and how mitotic inhibition of transcription drives mutually exclusive events. Cell Cycle 2007, 6:70-74.
16. Bleiberg H., Cvitkovic E. Characterisation and clinical management of CPT-11 (Irinotecan)-induced adverse events: The European perspective. European Journal of Cancer 1996, 32A(Suppl. 3):S18-S23.
17. Bode A.M., Dong Z. Cancer prevention research-Then and now. Nature Reviews. Cancer 2009, 9:508-516.
18. Bouwmeester H.J., Matusova R., Sun Z., Beale M.H. Secondary metabolite signalling in host-parasitic plant interactions. Current Opinion in Plant Biology 2003, 6:358-364.
19. Brangi M., Litman T., Ciotti M., Nishiyama K., Kohlhagen G., Takimoto C., Robey R., Pommier Y., Fojo T., Bates S.E. Camptothecin resistance: Role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Research 1999, 59:5938-5946.
20. Buchanan B., Gruissem W., Jones R.L. Biochemistry & Molecular Biology of Plants 2002, American Society of Plant Physiologists, Rockville, MD.
21. Chabalier C., Lamare C., Racca C., Privat M., Valette A., Larminat F. BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 2006, 5:1001-1007.
22. Chase M. Clashing priorities: A new cancer drug may extend lives. Wall Street Journal, New York 1991, 9:A1.
23. Chavan S.P., Venkatraman M.S. A practical and efficient synthesis of (+/-)-camptothecin. Tetrahedron Letters 1998, 39:6745-6748.
24. Chen X., Zheng Y., Zhu J., Jiang J., Wang J. p73 is transcriptionally regulated by DNA damage. Oncogene 2001, 20:769-774.
25. Cheng S., Evans W.K., Stys-Norman D., Shepherd F.A. Chemotherapy for relapsed small cell lung cancer: A systematic review and practice guideline. Journal of Thoracic Oncology 2007, 2:348-354. Lung Canc Dis Site Grp Canc Care O.
26. Chu Q., Vincent M., Logan D., Mackay J.A., Evans W.K. Taxanes as first-line therapy for advanced non-small cell lung cancer: A systematic review and practice guideline. Lung Cancer 2005, 50:355-374.
27. Ciufolini M.A., Roschangar F. Total synthesis of (+)-camptothecin. Angewandte Chemie International Edition in English 1996, 35:1692-1694.
28. Ciufolini M.A., Roschangar F. Practical total synthesis of (+)-camptothecin: The full story. Tetrahedron 1997, 53:11049-11060.
29. Ciufolini M.A., Roschangar F. Practical synthesis of (20 S)-(+)-camptothecin: The progenitor of a promising group of anticancer agent. Targets in Heterocyclic Systems 2000, 4:25.
30. Combes O., Barre J., Duche J.C., Vernillet L., Archimbaud Y., Marietta M.P., Tillement J.P., Urien S. In vitro binding and partitioning of irinotecan (CPT-11) and its metabolite, SN-38, in human blood. Investigational New Drugs 2000, 18:1-5.
31. Comins D.L., Nolan J.M. A practical six-step synthesis of (S)-camptothecin. Organic Letters 2001, 3:4255-4257.
32. Cragg G.M., Newman D.J. A tale of two tumor targets: Topoisomerase I and tubulin. The Wall and Wani contribution to cancer chemotherapy. Journal of Natural Products 2004, 67:232-244.
33. Cragg G.M., Kingston D.G.I., Newman D.J. Anticancer Agents from Natural Sources 2005, CRC Press/Taylor & Francis, Boca Raton, FL.
34. Croteau R., Ketchum R.E.B., Long R.M., Kaspera R., Wildung M.R. Taxol biosynthesis and molecular genetics. Phytochemistry Reviews 2006, 5:75-97.
35. Cunningham D., Pyrhonen S., James R.D., Punt C.J.A., Hickish T.F., Heikkila R., Johannesen T.B., Starkhammar H., Topham C.A., Awad L., Jacques C., Herait P. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998, 352:1413-1418.
36. Curran D.P., Liu H. New 4+1 radical annulations-A formal total synthesis of (+/-)-camptothecin. Journal of the American Chemical Society 1992, 114:5863-5864.
37. Das T., Sa G., Saha B., Das K. Multifocal signal modulation therapy of cancer: Ancient weapon. Molecular and Cellular Biochemistry 2010, 336:85-95.
38. de Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., Boni C., Cortes-Funes H., Cervantes A., Freyer G., Papamichael D., Le Bail N., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. Journal of Clinical Oncology 2000, 18:2938-2947.
39. de Jonge M.J.A. Inter- and intrapatient variability in oral topotecan pharmacokinetics: Implications for body-surface area dosage regimens. Clinical Cancer Research 2000, 6:2685-2689.
40. Decottignies A., Lambert L., Catty P., Degand H., Epping E.A., Moyerowley W.S., Balzi E., Goffeau A. Identification and characterization of SNQ2, a new multidrug ATP binding cassette transporter of the yeast plasma-membrane. Journal of Biological Chemistry 1995, 270:18150-18157.
41. Denis J.N., Greene A.E., Guenard D., Gueritte-Voegelein F., Mangatal L., Potier P. A highly efficient, practical approach to natural taxol. Journal of the American Chemical Society 1988, 110:5917-5919.
42. D'Incalci M., Steward W., Gescher A. Use of cancer chemopreventive phytochemicals as antineoplastic agents. The Lancet Oncology 2005, 6:899-904.
43. Dizon D.S., Hensley M.L., Poynor E.A., Sabbatini P., Aghajanian C., Hummer A., Venkatraman E., Spriggs D.R. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: Application toward a dynamic disease state model of ovarian cancer. Journal of Clinical Oncology 2002, 20:1238-1247.
44. Dodds H.M., Rivory L.P. The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11). Molecular Pharmacology 1999, 56:1346-1353.
45. Dombernowsky P., Gehl J., Boesgaard M., Paaske T., Jensen B.V. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer. Seminars in Oncology 1996, 23:23-27.
46. Dorr R.T. Pharmacology and toxicology of Cremophor EL diluent. The Annals of Pharmacotherapy 1994, 28:S11-S14.
47. Douillard J.Y., Cunningham D., Roth A.D., Navarro M., James R.D., Karasek P., Jandik P., Iveson T., Carmichael J., Alakl M., Gruia G., Awad L., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000, 355:1041-1047.
48. Doyle L.A., Yang W.D., Abruzzo L.V., Krogmann T., Gao Y.M., Rishi A.K., Ross D.D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:15665-15670.
49. Drukman S., Kavallaris M. Microtubule alterations and resistance to tubulin-binding agents (review). International Journal of Oncology 2002, 21:621-628.
50. Eckardt J.R., von Pawel J., Pujol J.L., Papai Z., Quoix E., Ardizzoni A., Poulin R., Preston A.J., Dane G., Ross G. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. Journal of Clinical Oncology 2007, 25:2086-2092.
51. Eisenhauer E.A., Huinink W.W.t.B., Swenerton K.D., Gianni L., Myles J., Burg M.E.v.d., Kerr I., Vermorken J.B., Buser K., Colombo N. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology 1994, 12:2654-2666.
52. Ejima A., Terasawa H., Sugimori M., Tagawa H. Antitumor agents. 1. Asymmetric-synthesis of (S)-camptothecin. Tetrahedron Letters 1989, 30:2639-2640.
53. Fang J., Seki T., Maeda H. Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Advanced Drug Delivery Reviews 2009, 61:290-302.
54. Fellner S., Bauer B., Miller D.S., Schaffrik M., Fankhänel M., Spruß T., Bernhardt G., Graeff C., Färber L., Gschaidmeier H., Buschauer A., Fricker G. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. Journal of Clinical Investigation 2002, 110:1309-1318.
55. Fields A.L., Einstein M.H., Novetsky A.P., Gebb J., Goldberg G.L. Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC). Gynecologic Oncology 2008, 108:201-206.
56. Fujimori A., Harker W.G., Kohlhagen G., Hoki Y., Pommier Y. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Research 1995, 55:1339-1346.
57. Gandia D., Abigerges D., Armand J.P., Chabot G., Da Costa L., De Forni M., Mathieu-Boue A., Herait P. CPT-11 induced cholinergic effects in cancer patients. Journal of Clinical Oncology 1993, 11:196-197.
58. Garcia-Carbonero R., Supko J.G. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clinical Cancer Research 2002, 8:641-661.
59. Gerven J.M.v., Moll J.W., Bent M.J.v.d., Bontenbal M., Burg M.E.v.d., Verweij J., Vecht C.J. Paclitaxel (Taxol) induces cumulative mild neurotoxicity. European Journal of Cancer 1994, 30A:1074-1077.
60. Gianni L., Kearns C., Giani A., Capri G., Viganó L., Lacatelli A., Bonadonna G., Egorin M. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. Journal of Clinical Oncology 1995, 13:180-190.
61. Gilmore P.M., McCabe N., Quinn J.E., Kennedy R.D., Gorski J.J., Andrews H.N., McWilliams S., Carty M., Mullan P.B., Duprex W.P., Liu E.T., Johnston P.G., et al. BRCA1 interacts with and is required for paclitaxel-induced activation of mitogen-activated protein kinase kinase kinase 3. Cancer Research 2004, 64:4148-4154.
62. Gore M., ten Bokkel Huinink W., Carmichael J., Gordon A., Davidson N., Coleman R., Spaczynski M., Heron J.F., Bolis G., Malmstrom H., Malfetano J., Scarabelli C., et al. Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovarian cancer. Journal of Clinical Oncology 2001, 19:1893-1900.
63. Gottesman M.M. Mechanisms of cancer drug resistance. Annual Review of Medicine 2002, 53:615-627.
64. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annual Review of Biochemistry 1993, 62:385-427.
65. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., Hawkins M., O'Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. Journal of Clinical Oncology 2005, 23:7794-7803.
66. Greenwald P. Cancer chemoprevention. British Medical Journal 2002, 324:714-718.
67. Gueritte-Voegelein F., Guenard D., Lavelle F., Le Goff M.T., Mangatal L., Potier P. Relationships between the structure of taxol analogues and their antimitotic activity. Journal of Medicinal Chemistry 1991, 34:992-998.
68. Guichard S., Terret C., Hennebelle I., Lochon I., Chevreau P., Fretigny E., Selves J., Chatelut E., Bugat R., Canal P. CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues. British Journal of Cancer 1999, 80:364-370.
69. Haldar S., Basu A., Croce C. Bcl2 is the guardian of microtubule integrity. Cancer Research 1997, 57:229-233.
70. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
71. Henderson I.C., Berry D.A., Demetri G.D., Cirrincione C.T., Goldstein L.J., Martino S., Ingle J.N., Cooper M.R., Hayes D.F., Tkaczuk K.H., Fleming G., Holland J.F., et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. Journal of Clinical Oncology 2003, 21:976-983.
72. Henegar K.E., Ashford S.W., Baughman T.A., Sih J.C., Gu R.L. Practical asymmetric synthesis of (S)-4-ethyl-7,8-dihydro-4-hydroxy-1H-pyrano 3,4-f indolizine-3,6,10(4H)-trione, a key intermediate for the synthesis of irinotecan and other camptothecin analogs. Journal of Organic Chemistry 1997, 62:6588-6597.
73. Henningsson A., Karlsson M.O., Viganó L., Gianni L., Verweij J., Sparreboom A. Mechanism-based pharmacokinetic model for paclitaxel. Journal of Clinical Oncology 2001, 19:4065-4073.
74. Herben V.M.M., ten Bokkel Huinink W.W., Dubbelman A.C., Mandjes I.A., Groot Y., van Gortel-van Zomeren D.M., Beijnen J.H. Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide. British Journal of Cancer 1997, 76:1500-1508.
75. Herben V.M.M., Huinink W.W.T., Schellens J.H.M., Beijnen J.H. Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors. Pharmacy World & Science 1998, 20:161-172.
76. Herben V.M.M., Rosing H., ten Bokkel Huinink W.W., van Zomeren D.M., Batchelor D., Doyle E., Beusenberg F.D., Beijnen J.H., Schellens J.H. Oral topotecan: Bioavailability and effect of food co-administration. British Journal of Cancer 1999, 80:1380-1386.
77. Herzog T.J. Update on the role of topotecan in the treatment of recurrent ovarian cancer. The Oncologist 2002, 7:3-10.
78. Hosomi Y., Shibuya M., Niho S., Ichinose Y., Kiura K., Sakai H., Takeda K., Kudo S., Eguchi K., Matsui K., Masuda N., Ando M., et al. Phase II study of topotecan with cisplatin in Japanese patients with small cell lung cancer. Anticancer Research 2011, 31:3449-3456.
79. Hou C.-C., Chen Y.-P., Wu J.-H., Huang C.-C., Wang S.-Y., Yang N.-S., Shyur L.-F. A galactolipid possesses novel cancer chemopreventive effects by suppressing inflammatory mediators and mouse B16 melanoma. Cancer Research 2007, 67:6907-6915.
80. Hsan K.M., Chen C.-C., Shyur L.-F. Current research and development of chemotherapeutic agents for melanoma. Cancers 2010, 2:397-419.
81. Hsiang Y.H., Hertzberg R., Hecht S., Liu L.F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase-I. Journal of Biological Chemistry 1985, 260:4873-4878.
82. Huang T.T., Wuerzberger-Davis S.M., Seufzer B.J., Shumway S.D., Kurama T., Boothman D.A., Miyamoto S. NF-kB activation by camptothecin: A linkage between nuclear DNA damage and cytoplasmic signaling events. Journal of Biological Chemistry 2000, 275:9501-9509.
83. Huang C.-C., Lo C.-P., Chiu C.-Y., Shyur L.-F. Deoxyelephantopin, a novel multifunctional agent suppresses mammary tumor growth and lung metastasis and doubles survival time in mice. British Journal of Pharmacology 2010, 159:856-871.
84. Ibrahim N.K., Desai N., Legha S., Soon-Shiong P., Theriault R.L., Rivera E., Esmaeli B., Ring S.E., Bedikian A., Hortobagyi G.N., Ellerhorst J.A. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clinical Cancer Research 2002, 8:1038-1044.
85. Ichinose Y., Seto T., Nishiwaki Y., Kiura K., Sakai H., Yokoyama A., Segawa Y., Ando M., Watanabe K. Phase I study of topotecan and cisplatin in patients with small cell lung cancer. Japanese Journal of Clinical Oncology 2011, 41:197-203.
86. Ikeguchi M., Arai Y., Maeta Y., Ashida K., Katano K., Wakatsuki T. Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer. Surgery Today 2011, 41:1196-1199.
87. Iyer L., King C.D., Whitington P.F., Green M.D., Roy S.K., Tephly T.R., Coffman B.L., Ratain M.J. Genetic predisposition to the metabolism of irinotecan (CPT-11). Journal of Clinical Investigation 1998, 101:847-854.
88. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA: A Cancer Journal for Clinicians 2010, 60:277-300.
89. Jennewein S., Wildung M.R., Chau M., Walker K., Croteau R. Random sequencing of an induced Taxus cell cDNA library for identification of clones involved in Taxol biosynthesis. Proceedings of the National Academy of Sciences 2004, 101:9149-9154.
90. Jordan M.A., Wilson L. Microtubules as a target for anticancer drugs. Nature Reviews. Cancer 2004, 4:253-265.
91. Katzmann D.J., Hallstrom T.C., Voet M., Wysock W., Golin J., Volckaert G., Moylerowley W.S. Expression of an ATP-binding cassette transporter-encoding gene (YOR1) is required for oligomycin resistance in Saccharomyces cerevisiae. Molecular and Cellular Biology 1995, 15:6875-6883.
92. Kaufman P.B., Pennacchini L., McKenzie M., Hoyt J.E. Good and bad uses of these compounds by humans. Natural Products from Plants 1998, 123-155. CRC Press LLC, Boca Raton, FL. P.B. Kaufman, L.J. Cseke, S. Warber, J.A. Duke, H.L. Brielmann (Eds.).
93. Kehrer D.F.S., Yamamoto W., Verweij J., de Jonge M.J.A., de Bruijn P., Sparreboom A. Factors involved in prolongation of the terminal disposition phase of SN-38: Clinical and experimental studies. Clinical Cancer Research 2000, 6:3451-3458.
94. Kehrer D.F.S., Soepenberg O., Loos W.J., Verweij J., Sparreboom A. Modulation of camptothecin analogs in the treatment of cancer: A review. Anticancer Drugs 2001, 12:89-105.
95. Kelling J., Sullivan K., Wilson L., Jordan M.A. Suppression of centromere dynamics by Taxol® in living osteosarcoma cells. Cancer Research 2003, 63:2794-2801.
96. Khanna R., Morton C.L., Danks M.K., Potter P.M. Proficient metabolism of CPT-11 by a human intestinal carboxylesterase. Cancer Research 2000, 60:4725-4728.
97. Kinghorn A.D., Pan L., Fletcher J.N., Chai H. The relevance of higher plants in lead compound discovery programs. Journal of Natural Products 2011, 74:1539-1555.
98. Kingston D.G.I. The shape of things to come: Structural and synthetic studies of taxol and related compounds. Phytochemistry 2007, 68:1844-1854.
99. Kingston D., Jagtop P., Yuan Y., Samala L. The chemistry of Taxol and related taxoids. Progress in the Chemistry of Organic Natural Products 2002, 84:56-225.
100. Kollmannsberger C., Mross K., Jakob A., Kanz L., Bokemeyer C. Topotecan-A novel topoisomerase I inhibitor: Pharmacology and clinical experience. Oncology (Williston Park, N.Y.) 1999, 56:1-12.
101. Konkimalla V.B., Efferth T. Inhibition of epidermal growth factor receptor-overexpressing cancer cells by camptothecin, 20-(N, N-diethyl) glycinate. Biochemical Pharmacology 2010, 80:39-49.
102. Kumar G., Walle U., Bhalla K., Walle T. Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein. Research Communications in Chemical Pathology and Pharmacology 1993, 80:337-344.
103. Labbozzetta M., Notarbartolo M., Poma P., Maurici A., Inguglia L., Marchetti P., Rizzi M., Baruchello R., Simoni D., D'Alessandro N. Curcumin as a possible lead compound against hormone-independent, multidrug-resistant breast cancer. Annals of the New York Academy of Sciences 2009, 1155:278-283.
104. Lee W.-L., Wen T.-N., Shiau J.-Y., Shyur L.-F. Differential proteomic profiling identifies novel molecular targets of paclitaxel and phytoagent deoxyelephantopin against mammary adenocarcinoma cells. Journal of Proteome Research 2010, 9:237-253.
105. Lee W.K., Bode A.M., Dong Z. Molecular targets of phytochemicals for cancer prevention. Nature Reviews. Cancer 2011, 11:211-218.
106. Leistner E. Arzneimittel aus der natur. Die biologie der taxane. Pharmazie in Unserer Zeit 2005, 34:98-103.
107. Levine A.J. p53, the cellular gatekeeper review for growth and division. Cell 1997, 88:323-331.
108. Li Q.Y., Zu Y.G., Shi R.Z., Yao L.P. Review camptothecin: Current perspectives. Current Medicinal Chemistry 2006, 13:2021-2039.
109. Li Y., Goodwin C.R., Sang Y., Rosen E., Laterra J., Xia S. Camptothecin and Fas receptor agonists synergistically induce medulloblastoma cell death: ROS-dependent mechanisms. Anti-Cancer Drugs 2009, 20:770-778.
110. Lilenbaum R., Ratain M., Miller A., Hargis J., Hollis D., Rosner G., O'Brian S., Brewster L., Green M., Schilsky R. Phase I study of paclitaxel and topotecan in patients with advanced tumors: A cancer and leukemia group B study. Journal of Clinical Oncology 1995, 13:2230-2237.
111. Lin A., Karin M. NF-kappaB in cancer: A marked target. Seminars in Cancer Biology 2003, 13:107-114.
112. Ling Y.H., Tornos C., Perez-Soler R. Phosphorylation of bcl-2 is a marker of M phase events and not a determinant of apoptosis. Journal of Biological Chemistry 1998, 273:18984-18991.
113. Ling Y.H., Donato N.J., Perez-Soler R. Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines. Cancer Chemotherapy and Pharmacology 2001, 47:473-480.
114. Lipton R., Apfel S., Dutcher J., Rosenberg R., Kaplan J., Berger A., Einzig A., Wiernik P., Schaumburg H. Taxol produces a predominantly sensory neuropathy. Neurology 1989, 39:368-373.
115. Liu L.F., Duan P., Lin C.T., D'arpa P., Wu J. Mechanism of action of camptothecin. Annals of the New York Academy of Sciences 1996, 803:44-49.
116. Long R.M., Lagisetti C., Coates R.M., Croteau R.B. Specificity of the N-benzoyl transferase responsible for the last step of Taxol biosynthesis. Archives of Biochemistry and Biophysics 2008, 477:384-389.
117. Longley D., Johnston P. Molecular mechanisms of drug resistance. The Journal of Pathology 2005, 205:275-292.
118. Lopez-Lazaro M. Anticancer and carcinogenic properties of curcumin: Considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Molecular Nutrition & Food Research 2008, 52:S103-S127.
119. Lorence A., Nessler C.L. Molecules of interest-Camptothecin, over four decades of surprising findings. Phytochemistry 2004, 65:2735-2749.
120. Lorenz W., Reimann H., Schmal A., Dormann P., Schwarz B., Neugebauer E., Doenicke A. Histamine release in dogs by Cremophor E1 and its derivatives: Oxethylated oleic acid is the most effective constituent. Agents and Actions 1977, 7:63-67.
121. Lu A.J., Zhang Z.S., Zheng M.Y., Zou H.J., Luo X.M., Jiang H.L. 3D-QSAR study of 20 (S)-camptothecin analogs. Acta Pharmacologica Sinica 2007, 28:307-314.
122. Luch A. Molecular, Clinical and Environmental Toxicology 2009, Birkhäuser Verlag AG, Berlin.
123. Mabuchi S., Ohmichi M., Nishio Y., Hayasaka T., Kimura A., Ohta T., Kawagoe J., Takahashi K., Yada-Hashimoto N., Seino-Noda H., Sakata M., Motoyama T., et al. Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Clinical Cancer Research 2004, 10:7645-7654.
124. Mackler N.J., Pienta K.J. Drug insight: Use of docetaxel in prostate and urothelial cancers. Nature Clinical Practice Urology 2005, 2:92-100.
125. Mangatal L., Adeline M.T., Guenard D., Gueritte-Voegelein F., Potier P. Application of the vicinal oxyamination reaction with asymmetric induction to the hemisynthesis of taxol and analogues. Tetrahedron 1989, 45:177-190.
126. Marsh S., Hoskins J.M. Irinotecan pharmacogenomics. Pharmacogenomics 2010, 11:1003-1010.
127. Marsh S., McLeod H.L. Pharmacogenetics of irinotecan toxicity. Pharmacogenomics 2004, 5:835-843.
128. Marupudi N.I., Han J.E., Li K.W., Renard V.M., Tyler B.M., Brem H. Paclitaxel: A review of adverse toxicities and novel delivery strategies. Expert Opinion on Drug Safety 2007, 6:609-621.
129. Mathijssen R.H.J., Loos W.J., Verweij J., Sparreboom A. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Current Cancer Drug Targets 2002, 2:103-123.
130. Mattern M.R., Hofmann G.A., Polsky R.M., Funk L.R., McCabe F.L., Johnson R.K. In vitro and in vivo effects of clinically important camptothecin analogs on multidrug-resistant cells. Oncology Research 1993, 5:467-474.
131. McChesney J.D., Venkataraman S.K., Henri J.T. Plant natural products: Back to the future or into extinction?. Phytochemistry 2007, 68:2015-2022.
132. McCoy M. Lining up to make a cancer drug. Chemical & Engineering News 2004, 82:12-14.
133. McGrogan B.T., Gilmartin B., Carney D.N., McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochimica et Biophysica Acta 2008, 1785:96-132.
134. Mielke S., Mross K., Gerds T., Schmidt A., Wäsch R., Berger D., Lange W., Behringer D. Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h. Anti-Cancer Drugs 2003, 14:785-792.
135. Moertel C.G., Hahn R.G., Schutt A.J., Reitemei R. Phase II study of camptothecin (NSC-100880) in treatment of advanced gastrointestinal cancer. Cancer Chemotherapy Reports 1972, 56(1):95-101.
136. Montazeri A., Boucaud M., Lokiec F., Pinguet F., Culine S., Deporte-Fety R., Albin N., Laguerre B., Goupil A., Bugat R., Canal P., Chatelut E. Population pharmacokinetics of topotecan: Intraindividual variability in total drug. Cancer Chemotherapy and Pharmacology 2000, 46:375-381.
137. Mullan P.B., Quinn J.E., Gilmore P.M., McWilliams S., Andrews H., Gervin C., McCabe N., McKenna S., White P., Song Y.-H., Maheswaran S., Liu E., et al. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 2001, 20:6123-6131.
138. Nakagawa H., Saito H., Ikegami Y., Aida-Hyugaji S., Seigo S., Ishikawa T. Molecular modeling of new camptothecin analogues to circumvent ABCG2-mediated drug resistance in cancer. Cancer Letters 2006, 234:81-89.
139. Nakatomi K., Yoshikawa M., Oka M., Ikegami Y., Hayasaka S., Sano K., Shiozawa K., Kawabata S., Soda H., Ishikawa T., Tanabe S., Kohno S. Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochemical and Biophysical Research Communications 2001, 288:827-832.
140. Nelson W.G., Kastan M.B. DNA strand breaks: The DNA template alterations that trigger p53-dependent DNA damage response pathways. Molecular and Cellular Biology 1994, 14:1815-1823.
141. Nicoletti M.I., Valoti G., Giannakakou P., Zhan Z., Kim J.-H., Lucchini V., Landoni F., Mayo J.G., Giavazzi R., Fojo T. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-anticancer drug screen: Correlation with sensitivity to microtubule active agents. Clinical Cancer Research 2001, 7:2912-2922.
142. Oakman C., Pestrin M., Cantisani E., Licitra S., DeStefanis M., Biganzoli L., Di Leo A. Adjuvant chemotherapy-The dark side of clinical trials. Have we learnt more?. Breast 2009, 18:S18-S24.
143. Oberlies N.H., Kroll D.J. Camptothecin and Taxol: Historic achievements in natural products research. Journal of Natural Products 2004, 67:129-135.
144. Oostendorp L.J.M., Stalmeier P.F., Pasker-de Jong P.C., Van der Graaf W.T., Ottevanger P.B. Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer. Anti-Cancer Drugs 2010, 21:749-758.
145. Orr G.A., Verdier-Pinard P., McDaid H., Horwitz S.B. Mechanisms of Taxol resistance related to microtubules. Oncogene 2003, 22:7280-7295.
146. Osheroff N. Biochemical basis for the interactions of type-I and type-II topoisomerases with DNA. Pharmacology and Therapeutics 1989, 41:223-241.
147. Ozols R.F. Future directions in the treatment of ovarian cancer. Seminars in Oncology 2002, 29:32-42.
148. Page C., Lin H.J., Jin Y., Castle V.P., Nunez G., Hunang M., Lin J. Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Research 2000, 20:407-416.
149. Park E.J., Pezzuto J.M. Botanicals in cancer chemoprevention. Cancer and Metastasis Reviews 2002, 21:231-255.
150. Patel N., Chatterjee S., Vrbanac V., Chung I., Mu C., Olsen R., Waghome C., Zetter B. Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cells. Proceedings of the National Academy of Sciences 2010, 107:2503-2508.
151. Peeters M., Price T.J., Cervantes A., Sobrero A.F., Ducreux M., Hotko Y., Andre T., Chan E., Lordick F., Punt C.J.A., Strickland A.H., Wilson G., et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. Journal of Clinical Oncology 2010, 28:4706-4713.
152. Peltier A., Russell J. Recent advances in drug-induced neuropathies. Current Opinion in Neurology 2002, 15:633-638.
153. Persinos, E.E. (1990). Washington Insight, 15 September 1990.
154. Pietta P.G. Flavonoids as antioxidants. Journal of Natural Products 2000, 63:1035-1042.
155. Pirker R., Berzinec P., Brincat S., Kasan P., Ostoros G., Pesek M., Plate S., Purkalne G., Rooneem R., Skrickova J., Stanculeanu D., Timcheva C., et al. Therapy of small cell lung cancer with emphasis on oral topotecan. Lung Cancer 2010, 70:7-13.
156. Plosker G.L., Keam S.J. Trastuzumab: A review of its use in the management of HER2-positive metastatic and early-stage breast cancer. Drugs 2006, 66:449-475.
157. Pommier Y. Topoisomerase I inhibitors: Camptothecins and beyond. Nature Reviews. Cancer 2006, 6:789-802.
158. Quinn J.E., Kennedy R.D., Mullan P.B., Gilmore P.M., Carty M., Johnston P.G., Harkin D.P. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Research 2003, 63:6221-6228.
159. Raskin I., Ribnicky D.M., Momarnytsky S., Ilic N., Poulev A., Borisjuk N., Brinker A., Moreno D.A., Ripoll C., Yakoby N., O'Neal J.M., Cornwell T., et al. Plants and human health in the twenty-first century. Trends in Biotechnology 2002, 20:522-531.
160. Raveh-Amit H., Hai N., Rotem-Dai N., Shahaf G., Gopas J., Livneh E. Protein kinase C eta activates NF-kappaB in response to camptothecin-induced DNA damage. Biochemical and Biophysical Research Communications 2011, 412:313-317.
161. Redinbo M.R., Champoux J.J., Hol W.G.J. Novel insights into catalytic mechanism from a crystal structure of human topoisomerase I in complex with DNA. Biochemistry 2000, 39:6832-6840.
162. Reid R.J.D., Kauh E.A., Bjornsti M.A. Camptothecin sensitivity is mediated by the pleiotropic drug resistance network in yeast. Journal of Biological Chemistry 1997, 272:12091-12099.
163. Rieder C.L., Maiato H. Stuck in division or passing through: What happens when cells cannot satisfy the spindle assembly checkpoint. Developmental Cell 2004, 7:637-651.
164. Riemsma R., Simons J.P., Bashir Z., Gooch C.L., Kleijnen J. Systematic review of topotecan (Hycamtin) in relapsed small cell lung cancer. BMC Cancer 2010, 10:436-447.
165. Roos W., Kaina B. DNA damage-induced cell death by apoptosis. Trends in Molecular Medicine 2006, 12:440-450.
166. Rosing H., Herben V.M.M., van Gortel-van Zomeren D.M., Hop E., Kettenes-van den Bosch J.J., ten Bokkel Huinink W.W., Beijnen J.H. Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan. Cancer Chemotherapy and Pharmacology 1997, 39:498-504.
167. Rosing H., van Zomeren D.M., Doyle E., Bult A., Beijnen J.H. O-glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyl topotecan. Anti-Cancer Drugs 1998, 9:587-592.
168. Rougier P., Van Cutsem E., Bajetta E., Niederle N., Possinger K., Labianca R., Navarro M., Morant R., Bleiberg H., Wils J., Awad L., Herait P., et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998, 352:1407-1412.
169. Rowinsky E.K., Donehower R.C. Paclitaxel (taxol). The New England Journal of Medicine 1995, 332:1004-1014.
170. Rowinsky E., Chaudhry V., Cornblath D., Donehower R. Neurotoxicity of taxol. Journal of the National Cancer Institute. Monographs 1993, 15:107-115.
171. Rowinsky E., Chaudhry V., Forastiere A., Sartorius S., Ettinger D., Grochow L., Lubejko B., Cornblath D., Donehower R. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: Neuromuscular toxicity is dose-limiting. Journal of Clinical Oncology 1993, 11:2010-2020.
172. Rudolf E., Rudolf K., Cervinka M. Camptothecin induces p53-dependent and -independent apoptogenic signaling in melanoma cells. Apoptosis 2011, 16:1165-1176.
173. Sahenk Z., Barohn R., New P., Mendell J. Taxol neuropathy. Electrodiagnostic and sural nerve biopsy findings. Archives of Neurology 1994, 51:726-729.
174. Saliba F., Hagipantelli R., Misset J., Bastian G., Vassal G., Bonnay M., Herait P., Cote C., Mahjoubi M., Mignard D., Cvitkovic E. Pathophysiology and therapy or irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: A prospective assessment. Journal of Clinical Oncology 1998, 16:2745-2751.
175. Saltz L.B., Cox J.V., Blanke C., Rosen L.S., Fehrenbacher L., Moore M.J., Maroun J.A., Ackland S.P., Locker P.K., Pirotta N., Elfring G.L., Miller L.L. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. The New England Journal of Medicine 2000, 343:905-914.
176. Santos A., Zanetta S., Cresteil T., Deroussent A., Pein F., Raymond E., Vernillet L., Risse M.L., Boige V., Gouyette A., Vassal G. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clinical Cancer Research 2000, 6:2012-2020.
177. Sarkar F.H., Li Y. Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Research 2006, 66:3347-3350.
178. Sarkar F., Li Y., Wang Z., Kong D. Cellular signaling perturbation by natural products. Cellular Signalling 2009, 21:1541-1547.
179. Sasaki Y., Hakusui H., Mizuno S., Morita M., Miya T., Eguchi K., Shinkai T., Tamura T., Ohe Y., Saijo N. A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38. Japanese Journal of Cancer Research 1995, 86:101-110.
180. Schiff P.B., Horwitz S.B. Taxol stabilizes microtubules in mouse fibroblast cells. Proceedings of the National Academy of Sciences 1980, 77:1561-1565.
181. Schiff P.B., Fant J., Horwitz S.B. Promotion of microtubule assembly in vitro by taxol. Nature 1979, 277:665-667.
182. Schiller J., Kim K., Hutson P., DeVore R., Glick J., Stewart J., Johnson D. Phase II study of topotecan in patients in extensive-stage small-cell carcinoma of the lung: An eastern cooperative oncology group trial. Journal of Clinical Oncology 1996, 14:2345-2352.
183. Schmitz G., Langmann T., Heimerl S. Role of ABCG1 and other ABCG family members in lipid metabolism. Journal of Lipid Research 2001, 42:1513-1520.
184. Scuteri A., Nicolini G., Miloso M., Bossi M., Cavaketti G., Windebank A.J., Tredici G. Paclitaxel toxicity in post-mitotic dorsal root ganglion (DRG) cells. Anticancer Research 2006, 26:1065-1070.
185. Shao R.G., Cao C.X., Zhang H., Kohn K.W., Wold M.S., Pommier Y. Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes. EMBO Journal 1999, 18:1397-1406.
186. Shitashige M., Toi M., Yano T., Shibata M., Matsuo T., Shibasaki F. Dissociation of Bax from a Bcl-2/Bax heterodimer triggered by phosphorylation of serine 70 of Bcl-2. Journal of Biological Chemistry 2001, 130:741-748.
187. Shyur L.-F., Yang N.-S. Metabolomics for phytomedicine research and drug development. Current Opinions in Chemical Biology 2008, 12:66-71.
188. Simizu S., Takada M., Umezawa K., Imoto M. Requirement of caspase-3(-like) protease-mediated hydrogen peroxide production for apoptosis induced by various anticancer drugs. Journal of Biological Chemistry 1998, 273:26900-26907.
189. Simpson D., Plosker G. Paclitaxel: As adjuvant or neoadjuvant therapy in early breast cancer. Drugs 2004, 64:1839-1847.
190. Slatter J.G., Schaaf L.J., Sams J.P., Feenstra K.L., Johnson M.G., Bombardt P.A., Cathcart K.S., Verburg M.T., Perarson L.K., Compton L.D., Miller L.L., Baker D.S., et al. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following i.v. infusion of [14C]CPT-11 in cancer patients. Drug Metabolism and Disposition 2000, 28:423-433.
191. Snyder J.P., Nettles J.H., Cornett B., Downing K.H., Nogales E. The binding conformation of Taxol in beta-tubulin: A model based on electron crystallographic density. Proceedings of the National Academy of Sciences 2001, 98:5312-5316.
192. Sonnichsen D., Relling M. Clinical pharmacokinetics of paclitaxel. Clinical Pharmacokinetics 1994, 27:256-269.
193. Sorger P.K., Dobles M., Tournebizet R., Hymant A.A. Coupling cell division and cell death to microtubule dynamics. Current Opinion in Cell Biology 1997, 9:807-814.
194. Sparreboom A., de Jonge M.J.A., de Bruijn P., Brouwer E., Nooter K., Loos W.J., van Alphen R.J., Mathijssen R.H.J., Stoter G., Verweij J. Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clinical Cancer Research 1998, 4:2747-2754.
195. Sparreboom A., Zuylen L.v., Brouwer E., Loos W.J., Bruijn P.d., Gelderblom H., Pillay M., Nooter K., Stoter G., Verweij J. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: Clinical pharmacokinetic implications. Cancer Research 1999, 59:1454-1457.
196. Spencer C., Faulds D. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1994, 48:794-847.
197. Sperker B., Backman J.T., Kroemer H.K. The role of beta-glucuronidase in drug disposition and drug targeting in humans. Clinical Pharmacokinetics 1997, 33:18-31.
198. Spigel D.R., Hainsworth J.D., Gandhi J.G., Gian V.G., Peyton J.D., West-Osterfield K., Clark B.L., Vazquez E.R., Jones S.F., Burris H.A., Greco F.A. A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancer. Journal of Thoracic Oncology 2010, 5:862-866.
199. Sporn M.B., Suh N. Chemoprevention: An essential approach to controlling cancer. Nature Reviews. Cancer 2002, 2:537-543.
200. Sporn M.B., Dunlop N.M., Newton D.L., Smith J.M. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Federation Proceedings 1976, 35:1332-1338.
201. Stark G.R., Taylor W.R. Control of the G2/M transition. Molecular Biotechnology 2006, 32:227-248.
202. Steller H. Mechanisms and genes of cellular suicide. Science 1995, 267:1445-1449.
203. Stewart Z.A., Mays D., Pietenpol J.A. Defective G1-S cell cycle checkpoint function sensitizes cells to microtubule inhibitor-induced apoptosis. Cancer Research 1999, 59:3831-3837.
204. Suffness M. Taxol: From discovery to therapeutic use. Annual Reports in Medicinal Chemistry 1993, 305-314. Academic Press, San Diego. J.A. Bristol (Ed.).
205. Suffness M., Wall M.E. Discovery and development of taxol. Taxol: Science and Applications 1995, 1-25. CRC Press, Boca Raton. M. Suffness (Ed.).
206. Surh Y.J. Cancer chemoprevention with dietary phytochemicals. Nature Reviews. Cancer 2003, 3:768-780.
207. Szebeni J., Muggia F.M., Alving C.R. Complement activation by cremophor EL as a possible contributor to hypersensitivity to paclitaxel: An in vitro study. Journal of the National Cancer Institute 1998, 90:300-306.
208. Takeya Y. Plant tissue culture of taxoids. Taxus: The Genus Taxus 2003, 134-150. Taylor and Francis, London. H. Itokawa, K.H. Lee (Eds.).
209. Tanizawa A., Fujimori A., Fujimori Y., Pommier Y. Comparison of topoisomerase-I inhibition, DNA-damage, and cytotoxicity of camptothecin derivatives presently in clinical-trials. Journal of the National Cancer Institute 1994, 86:836-842.
210. Tellingen O.v., Huizing M., Panday V.N., Schellens J., Nooijen W., Beijnen J. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. British Journal of Cancer 1999, 81:330-335.
211. Thomas C.J., Rahier N.J., Hecht S.M. Camptothecin: Current perspectives. Bioorganic & Medicinal Chemistry 2004, 12:1585-1604.
212. Tishler R.B., Schiff P.B., Geard C.R., Hall E.J. Taxol: A novel radiation sensitizer. International Journal of Radiation Oncology, Biology, Physics 1992, 22:613-617.
213. Tothova E., Fricova M., Stecova N., Kafkova A., Elbertova A. High expression of Bcl-2 protein in acute myeloid leukaemia cells is associated with poor response to chemotherapy. Neoplasma 2002, 49:141-144.
214. Tournigand C., Andre T., Achille E., Lledo G., Flesh M., Mery-Mignard D., Quinaux E., Couteau C., Buyse M., Ganem G., Landi B., Colin P., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. Journal of Clinical Oncology 2004, 22:229-237.
215. Tsao Y.P., Darpa P., Liu L.F. The involvement of active DNA synthesis in camptothecin-induced G2 arrest: Altered regulation of P34CDC2/cyclin B1. Cancer Research 1992, 52:1823-1829.
216. Tsao A.S., Kim E.S., Hong W.K. Chemoprevention of cancer. CA: A Cancer Journal for Clinicians 2004, 54:150-180.
217. Urasaki Y., Laco G.S., Pourquier P., Takebayashi Y., Kohlhagen G., Gioffre C., Zhang H.L., Chatterjee D., Pantazis P., Pommier Y. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line. Cancer Research 2001, 61:1964-1969.
218. Urist M., Tanaka T., Poyurovsky M., Prives C. p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes & Development 2004, 18:3041-3054.
219. Valero V., Forbes J., Pegram M.D., Pienkowski T., Eiermann W., Minckwitz G.v., Roche H., Martin M., Crown J., Mackey J.R., Fumoleau P., Rolski J., et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): Two highly active therapeutic regimens. Journal of Clinical Oncology 2011, 29:149-156.
220. Vallböhmer D., Iqbal S., Yang D.Y., Rhodes K.E., Zhang W., Gordon M., Fazzone W., Schultheis A.M., Sherrod A.E., Danenberg K.D., Lenz H.J. Molecular determinants of irinotecan efficacy. International Journal of Cancer 2006, 119:2435-2442.
221. van Cutsem E., Kohne C.H., Lang I., Folprecht G., Nowacki M.P., Cascinu S., Shchepotin I., Maurel J., Cunningham D., Tejpar S., Schlichting M., Zubel A., et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-Line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. Journal of Clinical Oncology 2011, 29:2011-2019.
222. Vara J.A.F., Casado E., Castro J.D., Cejas P., Belda-Iniesta C., Gonzalez-Baron M. PI3K/Akt signaling pathway and cancer. Cancer Treatment Reviews 2004, 30:193-204.
223. Verweij J., Clavelf M., Chevalier B. Paclitaxel (Taxol™) and docetaxel (Taxotere™): Not simply two of a kind. Annals of Oncology 1994, 5:495-505.
224. von Pawel J., Schiller J.H., Shepherd F.A., Fields S.Z., Kleisbauer J.P., Chrysson N.G., Stewart D.J., Clark P.I., Palmer M.C., Depierre A., Carmichael J., Krebs J.B., et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. Journal of Clinical Oncology 1999, 17:658-667.
225. von Pawel J., Gatzemeier U., Pujol J.L., Moreau L., Bildat S., Ranson M., Richardson G., Steppert C., Riviere A., Camlett I., Lane S., Ross G. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. Journal of Clinical Oncology 2001, 19:1743-1749.
226. Wakelee H., Ramalingam S., Belani C. Docetaxel in advanced non-small cell lung cancer. Expert Review of Anticancer Therapy 2005, 5:13-24.
227. Wall M.E. Camptothecin and taxol. Chronicles of Drug Discovery 1993, 153-165. American Chemical Society, Washington, DC. D. Lednicer (Ed.).
228. Wall M.E., Wani M.C. Taxol: Discovery to clinic. Economic and Medicinal Plant Research, Vol. 6 1994, 299-322. Academic Press, New York. H. Wagner, N.R. Farnsworth (Eds.).
229. Wall M.E., Wani M.C. Camptothecin and taxol: From discovery to clinic. Journal of Ethnopharmacology 1996, 51:239-254.
230. Wall M.E., Wani M.C., Cook C.E., Palmer K.H., McPhail A.T., Sim G.A. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. Journal of the American Chemical Society 1966, 88:3888-3890.
231. Wall M., Wani M., Taylor H. Isolation and chemical characterization of antitumor agents from plants. Cancer Treatment Report 1976, 60:1011-1030.
232. Wang T.H., Wang H.S., Ichijo H., Giannakakoui P., Foster J.S., Fojoi T., Wimalasena J. Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways. Journal of Biological Chemistry 1998, 279:4928-4936.
233. Wang T.H., Popp D.M., Wang H.S., Saitohi M., Mural J.G., Henley D.C., Ichijoi H., Wimalasena J. Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal Kinase (JNK)-dependent and -independent pathways in ovarian cancer cells. Journal of Biological Chemistry 1999, 274:8208-8216.
234. Wang T.H., Wang H.S., Soong Y.K. Paclitaxel-induced cell sheath: Where the cell cycle and apoptosis come together. Cancer 2000, 88:2619-2628.
235. Wang C.-Y., Staniforth V., Chiao M.-T., Hou C.-C., Wu H.-M., Yeh K.-C., Chen C.-H., Hwang P.-I., Wen T.-N., Shyur L.-F., Yang N.-S. Genomics and proteomics of immune modulatory effects of a butanol fraction of Echinacea purpurea in human dendritic cells. BMC Genomics 2008, 9:479-498.
236. Wani M.C., Taylor H.L., Wall M.E., Coggon P., McPhail A.T. Plant antitumor agents. VI. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. Journal of the American Chemical Society 1971, 93:2325-2327.
237. Weiss R.B., Donehower R.C., Wiernik P.H., Ohnuma T., Gralla R.J., Trump D.L., Baker J.R.J., Echo D.A.V., Hoff D.D.V., Leyland-Jones B. Hypersensitivity reactions from taxol. Journal of Clinical Oncology 1990, 8:1263-1268.
238. Wink M. Evolution of secondary metabolites from an ecological and molecular phylogenetic perspective. Phytochemistry 2003, 64:3-19.
239. Xia S., Rosen E.M., Laterra J. Sensitization of glioma cells to Fas-dependent apoptosis by chemotherapy-induced oxidative stress. Cancer Research 2005, 65:5248-5255.
240. Yabu K., Masumoto S., Yamasaki S., Hamashima Y., Kanai M., Du W., Curran D.P., Shibasaki M. Switching enantiofacial selectivities using one chiral source: Catalytic enantioselective synthesis of the key intermediate for (20S)-camptothecin family by (S)-selective cyanosilylation of ketones. Journal of the American Chemical Society 2001, 123:9908-9909.
241. Yabu K., Masumoto S., Kanai M., Curran D.P., Shibasaki M. Studies toward practical synthesis of (20S)-camptothecin family through catalytic enantioselective cyanosilylation of ketones: Improved catalyst efficiency by ligand-tuning. Tetrahedron Letters 2002, 43:2923-2926.
242. Yoshikawa M., Ikegami Y., Hayasaka S., Ishi K., Ito A., Sano K., Suzuki T., Togawa T., Yoshida E., Soda H., Oka M., Kohno S., et al. Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells. International Journal of Cancer 2004, 110:921-927.
243. Zhao E., Mu Q. Phytoestrogen biological actions on mammalian reproductive system and cancer growth. Scientia Pharmaceutica 2011, 79:1-20.
244. Zwenger S., Basu C. Plant terpenoids: Applications and future potentials. Biotechnology and Molecular Biology Reviews 2008, 3:1-7.